Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) announced on Friday that it has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection for cancer.

The all-stock transaction includes USD275m upfront and up to USD175m in earnouts tied to revenue and reimbursement milestones.

Foresight's PhasED-Seq technology enables detection of phased variants with LOD95 of 0.3 parts per million and sensitivity below 0.1 ppm.

This acquisition adds to Natera's portfolio of more than 500 issued or pending patents and strengthens its position in solid tumour MRD testing. The deal also accelerates Natera's expansion into lymphoma, where Foresight has established a strong clinical presence.

Combining Natera's commercial infrastructure with Foresight's technology aims to drive broader adoption of MRD testing across lymphoma and other solid tumours.

Foresight was founded by Stanford physicians and scientists, and has collaborated with over 30 biopharma and academic partners.